Click Therapeutics Stock
Digital Therapeutics Applications
Sign up today and learn more about Click Therapeutics Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Click Therapeutics Stock
Click Therapeutics, Inc. develops and commercializes software as prescription medical treatments for people with unmet medical needs. Through cognitive and neurobehavioral mechanisms, Click’s Digital Therapeutics™ enable change within individuals, and are designed to be used independently or in conjunction with biomedical treatments. The Clickometrics® adaptive data science platform continuously personalizes user experience to optimize engagement and outcomes. Following a groundbreaking clinical trial, Click’s industry-leading smoking cessation program is available nationwide through a wide variety of payers, providers, and employers. Click’s lead prescription program is entering into a multi-center, randomized, controlled, parallel-group, phase III FDA registration trial for the treatment of Major Depressive Disorder in adults.
Investors
Flatiron Investors
Hikma Ventures
K2 HealthVentures
Magellan Health Services
Sanofi
Funding History
| June 2018 | $33.1M |
|---|---|
| October 2021 | $57.8M |
Management
Chief Executive Officer
David Benshoof Klein
Chief Technology Officer
Christopher Jordan
Press
businesswire - Nov, 9 2023
Click Therapeutics Announces Participation in November Investor Conferencesfiercebiotech - Sep, 11 2023
Click Therapeutics teams up with addiction treatment maker Indivior to make digital therapeutics for substance use disordersfiercebiotech - May, 5 2023
Boehringer Ingelheim to test Click Therapeutics' digital schizophrenia app in the clinicbiospace - Dec, 19 2022
Boehringer Ingelheim and Click Therapeutics expand their existing Collaboration to develop Prescription Digital Therapeutics for Schizophreniamassdevice - Dec, 17 2022
Click Therapeutics wins FDA breakthrough nod for migraine-treating digital therapeuticiotone - Dec, 9 2022
How AI Can Democratize Healthcaremedium - Dec, 9 2022
Digital Therapeutics: The Basicsmedcitynews - Dec, 9 2022
How pharma companies can leverage asynchronous telemedicinebiospace - Apr, 15 2022
Click Therapeutics Closes $15 Million Debt Financing from Silicon Valley Bankbiospace - Feb, 24 2022
Altoida Announces Partnership with Click Therapeutics to Power Clinical Trials with Digital Cognitive Assessmentbiospace - Nov, 12 2021
Click Therapeutics to Participate in the BTIG Digital Health Forumfiercebiotech - Oct, 24 2021
With Sanofi still on board, Click Therapeutics closes $52M series B for digital therapeutics in depression, chronic pain and moremobihealthnews - Feb, 26 2021
Boehringer Ingelheim and Click Therapeutics talk about what makes DTx and pharma partnerships tickbuff - Feb, 25 2021
Otsuka, Click trial digital depression therapy with Googletrib - Sep, 15 2020
Boehringer Ingelheim and Click Therapeutics ink a $500 million dealmobihealthnews - Sep, 11 2020
Boehringer Ingelheim, Click Therapeutics ink $500M+ digital therapeutics development, commercialization dealendpts - Sep, 11 2020
After Novartis left, Boehringer bets up to $500M on the field of prescription smartphone appsEquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
